biologit

🚨 We’ve just launched Biologit for Local Literature™, a tech-powered managed service to automate one of the most painful gaps in pharmacovigilance. It’s a world-first in literature monitoring. One platform. Zero spreadsheets. Learn more from our latest White Paper: https://lnkd.in/ecYBhhwM

🚀 Introducing a World-First in Automated Local Literature Monitoring! 🌍📚 Be the first to discover a world-first innovation in automated local literature monitoring — solving one of pharma’s most time-consuming and compliance-critical challenges. This new white paper reveals how Biologit’s AI-driven platform streamlines global and local safety surveillance, reducing manual effort and regulatory risk. Download our white paper to explore further: https://lnkd.in/ecYBhhwM #pharmacovigilance #drugsafety #localliteraturemonitoring #AI #breakthrough #biologit

🚀 A world first in Pharmacovigilance is here! We are so proud to announce the launch of Biologit for Local Literature™ – the first-ever automated solution for screening non-indexed, local medical literature at scale. 15x faster than manual processes, covers all markets and languages and is already live and trusted by a top 10 global pharma company. This a breakthrough moment for drug safety and regulatory compliance. Read the full press release announcement here: https://lnkd.in/eiRpnE2i

Delighted to be a key exhibitor at World Drug Safety Congress Americas 2025! Look forward to meeting with our clients and partners in Boston.

💡Case Report Series with biologit Here at biologit, our vision is to ensure patient safety by simplifying the detection of risks and events from development to post-market. Our safety platform is uniquely designed to identify adverse events from the literature with our global and local database and purpose-built AI. Recently, our expert in PV/QA Manager, Sarah Jane Devaney, used the biologit platform to help uncover a case in the medical literature detailing the compassionate use of omadacycline in a child with Down syndrome and severe pneumonia caused by macrolide-resistant Mycoplasma pneumoniae, where the drug was used outside its approved indication. This underscores the importance of monitoring adverse events and efficacy to ensure patient safety and inform regulatory decisions regarding off-label treatments. Read more >>>

🚀 We’re at Why Summits Boston! Biologit is excited to be attending Why Summits American Drug Safety Summit Boston this week, where leaders in pharmacovigilance are coming together to explore the future of drug safety. Our CEO, Nicole Baker, will be delivering an insightful talk on March 13 at 11:00 AM: 🎤 "Accelerating Patient Safety: Leading with Evidence, AI, and Scientific Expertise" Nicole will dive into how AI is transforming pharmacovigilance, enhancing global and local literature surveillance. If you're attending, let’s connect! Looking forward to great discussions on the future of drug safety and innovation. #Pharmacovigilance #AI #DrugSafety #WhySummits #LifeSciences #Automation

🚀 Exciting News! Biologit is heading to Boston for the Why Summits American Drug Safety Summit on March 12-13! Join our CEO, Nicole Baker PhD, and COO, Jean Redmond, PhD to explore how automation can transform global and local literature searches in pharmacovigilance. 📢 Don't miss Nicole’s talk: 🗓 March 13 | 11:00 AM 🎤 "Accelerating Patient Safety: Leading with Evidence, AI, and Scientific Expertise" We’re looking forward to insightful discussions and meaningful connections—see you there! #Pharmacovigilance #DrugSafety #LiteratureMonitoring #WhySummits

A day packed with interesting topics and conversations!

💡Case Report Series with biologit Here at biologit, our vision is to ensure patient safety by simplifying the detection of risks and events from development to post-market. Our safety platform is uniquely designed to identify adverse events from the literature with our global and local database and purpose-built AI. Recently our PV Specialist/Veterinary Consultant Irina Constantin used the biologit platform to help uncover a rare case in the medical literature where a patient in China experienced dysphonia after cytarabine treatment. This case was found in the journal “Frontiers in Pharmacology” which is not indexed in PubMed and demonstrates the importance of searching a broad range of regional and local sources. Cytarabine is an antimetabolite and antineoplastic agent that inhibits DNA polymerase. This case study highlights the importance of closely monitoring side effects that impact patients' quality of life. Read more >>>

🚀 Kicking Off the European Drug Safety & PV Outsourcing Summit 2025! We’re excited to be in Barcelona for the Why Summits event, connecting with fellow leaders in pharmacovigilance. Join our CEO, Nicole Baker PhD, on Tuesday Feb 25th at 14:20, as she shares insights on the topic of AI in Pharmacovigilance: Streamlining Local and Global Literature Surveillance.   ✅ How AI is Transforming Literature Surveillance ✅ The Challenges and Opportunities for Local Literature ✅ Biologit’s AI Approach If you're attending, be sure to connect! 🔬✨ #Pharmacovigilance #AI #DrugSafety